查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1610271

多囊性肾病治疗药物市场：按类型、治疗、诊断、分销管道和最终用户分类 - 2025-2030 年全球预测

Polycystic Kidney Disease Drugs Market by Type (ADPKD, ARPKD), Treatment (Medication, Surgery), Diagnosis, Distribution Channels, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年多囊性肾治疗药物市值为5,1956万美元，预计2024年将达5,5,657万美元，复合年增长率为5.95%，到2030年将达7亿美元。

多囊性肾病变(PKD) 治疗市场研究透过专注于用于治疗PKD 的药物解决方案来分析其范围和定义，我正在捕获这种疾病，这是一种以肾臟中生长大量囊肿为特征的遗传性疾病。对 PKD 药物的需求源于 PKD 盛行率的增加和治疗方法的缺乏，以及控制症状和减缓疾病进展的需要。主要用途是控制高血压和抑制囊肿形成，针对发生率高于其他类型的常染色体显性多囊肾（ADPKD）患者。一系列最终用途包括医院、专科诊所和进行治疗和药物临床试验的研究实验室。

主要市场统计
基准年[2023] 51956万美元
预计年份 [2024] 55657万美元
预测年份 [2030] 77882万美元
复合年增长率（%） 5.95%

关键的成长要素包括基因研究的进步、提高早期诊断意识以及增加对新疗法研发的投资。市场开拓机会比比皆是，包括整合精准医疗来个人化治疗方法，以及与生技公司合作加速药物开发。为了利用这些优势，公司应该投资基因组技术并与学术机构建立合作关係以进行突破性研究。

市场开拓面临的挑战包括药物开发的高成本、严格的法规以及限制患者依从性的潜在副作用。此外，无症状病例的存在可能会阻碍早期的市场渗透策略，因为诊断主要是在后期进行的。利用人工智慧进行预测分析的创新治疗可以促进更有针对性的治疗方法，透过专注于联合治疗来提高治疗效果，并扩大治疗领域。

PKD 治疗市场的性质是动态的，跨国製药公司和新兴生物技术公司发挥关键作用。为了持续的业务成长，公司应该追求多元化的产品线，并专注于直接解决囊肿生长的药物，而不仅仅是控制症状。加强策略联盟和以患者为中心的方法对于克服市场挑战和抓住快速成长机会至关重要。

市场动态：快速发展的多囊性肾治疗市场的关键市场洞察

多囊性肾病药物市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 人群中慢性肾臟病的盛行率
    • 加强多囊性肾病变的合作与研究
    • 各国医疗保健支出增加
  • 市场限制因素
    • 製造复杂性
  • 市场机会
    • 市场参与者开拓先进药物
    • 策略联盟投资与产能扩张
  • 市场挑战
    • 品管问题

波特五力战略工具驾驭多囊性肾病药物市场

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对多囊性肾病药物市场的影响

外部宏观环境因素在塑造多囊性肾病治疗药物市场的表现动态中起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解多囊性肾治疗药物市场的竞争状况

对多囊性肾病治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵多囊性肾病变治疗市场供应商的绩效评估

FPNV 定位矩阵是评估多囊性肾病变治疗药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，为多囊性肾治疗药物市场的成功指明道路

对于希望加强在全球市场的影响力的公司来说，对多囊性肾病治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 人群中慢性肾臟病的盛行率
      • 加强多囊性肾病变的合作与研究
      • 经济体中的医疗成本增加
    • 抑制因素
      • 与生产相关的复杂性
    • 机会
      • 市场参与企业开发先进药物
      • 策略联盟和投资以扩大产能
    • 任务
      • 品管问题
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章多囊肾治疗药物市场：依类型

  • ADPKD
  • ARPKD

第七章依治疗分类的多囊性肾治疗药物市场

  • 药物治疗
  • 外科手术

第八章 多囊肾疾病诊断治疗药物市场

  • 电脑断层扫描
  • MRI
  • 超音波

第九章按通路分類的多囊性肾治疗药物市场

  • 医院药房
  • 零售药房

第 10 章 多囊性肾病治疗药物市场：依最终使用者分类

  • 医院/诊所
  • 专科诊所

第十一章 北美和南美多囊性肾治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区多囊性肾治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲多囊性肾病治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Apotex Inc.
  • AstraZeneca PLC
  • Centessa Pharmaceuticals Limited
  • Dr. Reddys Laboratories Ltd.
  • Galapagos NV
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Reata Pharmaceuticals Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • XORTX Therapeutics Inc.
Product Code: MRR-62667ADF9FE1

The Polycystic Kidney Disease Drugs Market was valued at USD 519.56 million in 2023, expected to reach USD 556.57 million in 2024, and is projected to grow at a CAGR of 5.95%, to USD 778.82 million by 2030.

Polycystic Kidney Disease (PKD) drugs market research captures the scope and definition by focusing on medication solutions used for managing PKD, a genetic disorder characterized by the growth of numerous cysts in the kidneys. The necessity for PKD drugs is driven by the increasing prevalence of the disease and the lack of curative treatments, necessitating management of symptoms and slowing disease progression. Applications primarily involve the control of hypertension and reduction of cyst formation, targeting patients with autosomal dominant PKD (ADPKD) due to its higher incidence compared to other types. End-use scope notably includes hospitals, specialty clinics, and research organizations where treatment and drug trials are conducted.

KEY MARKET STATISTICS
Base Year [2023] USD 519.56 million
Estimated Year [2024] USD 556.57 million
Forecast Year [2030] USD 778.82 million
CAGR (%) 5.95%

Key growth influencers include advancements in genetic research, heightened awareness leading to earlier diagnosis, and rising investments in R&D for novel therapeutics. The market is ripe with opportunities such as the integration of precision medicine to individualize treatment regimens and collaboration with biotechnology firms to accelerate drug development. To harness these, firms should invest in genomic technologies and establish partnerships with academic institutions for breakthrough research.

Challenges constricting market expansion encompass the high cost of drug development, stringent regulatory pathways, and potential side effects limiting patient compliance. Additionally, the existence of asymptomatic cases can impede early market penetration strategies, as diagnosis occurs predominantly at later stages. Innovating through AI for predictive analytics can facilitate more targeted treatment approaches, and focusing on combination therapies may enhance treatment efficacy and widen the therapeutic landscape.

The nature of the PKD drugs market is dynamic, with multinational pharmaceutical companies and emerging biotechnology firms playing significant roles. For sustained business growth, companies should pursue diversified pipelines, emphasizing drugs that not only manage symptoms but also address cyst growth directly. Enhancing strategic alliances and patient-centric approaches will be pivotal in overcoming both market challenges and seizing burgeoning opportunities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Polycystic Kidney Disease Drugs Market

The Polycystic Kidney Disease Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of chronic kidney disorders among population
    • Rising collaboration and research on polycystic kidney disease
    • Growing healthcare expenditure in economies
  • Market Restraints
    • Complexities associated with the production
  • Market Opportunities
    • Development of advanced medications by market players
    • Strategic alliances and investment for capacity expansion
  • Market Challenges
    • Issues pertaining to quality management

Porter's Five Forces: A Strategic Tool for Navigating the Polycystic Kidney Disease Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Polycystic Kidney Disease Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Polycystic Kidney Disease Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Polycystic Kidney Disease Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Polycystic Kidney Disease Drugs Market

A detailed market share analysis in the Polycystic Kidney Disease Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Polycystic Kidney Disease Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Polycystic Kidney Disease Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Polycystic Kidney Disease Drugs Market

A strategic analysis of the Polycystic Kidney Disease Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Polycystic Kidney Disease Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Apotex Inc., AstraZeneca PLC, Centessa Pharmaceuticals Limited, Dr. Reddys Laboratories Ltd., Galapagos NV, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Reata Pharmaceuticals Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., and XORTX Therapeutics Inc..

Market Segmentation & Coverage

This research report categorizes the Polycystic Kidney Disease Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across ADPKD and ARPKD.
  • Based on Treatment, market is studied across Medication and Surgery.
  • Based on Diagnosis, market is studied across CT Scan, MRI, and Ultra Sound.
  • Based on Distribution Channels, market is studied across Hospital Pharmacy and Retail Pharmacy.
  • Based on End-User, market is studied across Hospital & Clinics and Speciality Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic kidney disorders among population
      • 5.1.1.2. Rising collaboration and research on polycystic kidney disease
      • 5.1.1.3. Growing healthcare expenditure in economies
    • 5.1.2. Restraints
      • 5.1.2.1. Complexities associated with the production
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of advanced medications by market players
      • 5.1.3.2. Strategic alliances and investment for capacity expansion
    • 5.1.4. Challenges
      • 5.1.4.1. Issues pertaining to quality management
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Polycystic Kidney Disease Drugs Market, by Type

  • 6.1. Introduction
  • 6.2. ADPKD
  • 6.3. ARPKD

7. Polycystic Kidney Disease Drugs Market, by Treatment

  • 7.1. Introduction
  • 7.2. Medication
  • 7.3. Surgery

8. Polycystic Kidney Disease Drugs Market, by Diagnosis

  • 8.1. Introduction
  • 8.2. CT Scan
  • 8.3. MRI
  • 8.4. Ultra Sound

9. Polycystic Kidney Disease Drugs Market, by Distribution Channels

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Retail Pharmacy

10. Polycystic Kidney Disease Drugs Market, by End-User

  • 10.1. Introduction
  • 10.2. Hospital & Clinics
  • 10.3. Speciality Clinics

11. Americas Polycystic Kidney Disease Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Polycystic Kidney Disease Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Polycystic Kidney Disease Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Apotex Inc.
  • 3. AstraZeneca PLC
  • 4. Centessa Pharmaceuticals Limited
  • 5. Dr. Reddys Laboratories Ltd.
  • 6. Galapagos NV
  • 7. Johnson & Johnson Services, Inc.
  • 8. Merck & Co., Inc.
  • 9. Novartis AG
  • 10. Otsuka Pharmaceutical Co., Ltd.
  • 11. Reata Pharmaceuticals Inc.
  • 12. Sanofi S.A.
  • 13. Teva Pharmaceutical Industries Ltd.
  • 14. XORTX Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ADPKD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ARPKD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ULTRA SOUND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SPECIALITY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 127. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 217. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 232. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 233. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023